Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.
- Authors
- Type
- Published Article
- Journal
- Diabetes Care
- Publisher
- American Diabetes Association
- Publication Date
- 2009
- Volume
- 14
- Issue
- 1
- Pages
- 93–97
- Identifiers
- PMID: 19320241
- Source
- USPC - SET - SVS
- License
- Unknown
Abstract
HIV-1 RNA measured at baseline or at week 4 and HIV-1 subtype (B versus non-B) were independent predictive factors of VR in patients starting therapy with LPV/r alone. Although based on a small sample size, results of this study showed that adherence to therapy is lower in patients harbouring non-B subtypes and appears to be a key factor of VR in the context of protease inhibitor monotherapy.
